A clinical decision support system to improve adequate dosing of gentamicin and vancomycin

OBJECTIVE Gentamicin and vancomycin meet the criteria for measuring plasma concentrations during therapy. However, compliance with the accompanying guidelines remains low. The primary objective of this study was to determine whether the implementation of a clinical decision support system, which displays an alert if a plasma concentration should be measured and a daily reviewed patient list resulted in improved compliance. MATERIALS AND METHODS This intervention study was performed at the Spaarne Gasthuis, Haarlem/Hoofddorp, the Netherlands. The authors included 261 treatments with either gentamicin or vancomycin intravenously for at least 48 h in the year before and after implementation of the clinical decision support system in May 2015. The authors analyzed whether plasma concentrations were measured sooner and more frequently after the implementation, and determined whether the time until the correct dosage, with adequate drug concentrations, was reduced after implementation. RESULTS Before implementation, plasma concentrations were measured within 72 h in 47% of the treatments. After implementation, this percentage increased to 80% (p < 0.01). After implementation, the time was significantly shorter until the correct dosage was given. CONCLUSION The implementation of a clinical decision support system and a patient list resulted in improved compliance with the guidelines and optimized the treatment with gentamicin and vancomycin.

[1]  Robert J. Adams,et al.  Clinical decision support implemented with academic detailing improves prescribing of key renally cleared drugs in the hospital setting , 2010, J. Am. Medical Informatics Assoc..

[2]  V. Rollason,et al.  Impact of Clinical Decision Support Guidelines on Therapeutic Drug Monitoring of Gentamicin in Newborns , 2014, Therapeutic drug monitoring.

[3]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[4]  C. Frei,et al.  Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[5]  A Abu-Hanna,et al.  Five years of therapeutic drug monitoring in the intensive care did not change vancomycin prescription behaviour: perceived needs for decision support. , 2012, Minerva anestesiologica.

[6]  A H Thomson,et al.  Cost-Effectiveness of Therapeutic Drug Monitoring: A Systematic Review , 2005, Therapeutic drug monitoring.

[7]  R. Moore,et al.  Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. , 1987, The Journal of infectious diseases.

[8]  A. Vinks,et al.  Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. , 1999, Therapeutic drug monitoring.

[9]  S. Zhai,et al.  Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis , 2013, PloS one.